17:59 , Nov 2, 2016 |  BC Week In Review  |  Clinical News

THN102: Ph II started

Theranexus began a double-blind, placebo-controlled, 3-way crossover, French Phase II trial to compare 300 mg oral modafinil plus 3 and 27 mg oral flecainide vs. 300 mg modafinil alone in 2-weeks periods in about 48...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

THN102: Phase Ib started

Theranexus began a double-blind, placebo-controlled, French Phase Ib trial to evaluate 3 doses of THN102 in sleep-deprived volunteers. Theranexus , Orsay, France   Product: THN102   Business: Neurology   Molecular target: NA   Description: Combination...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Company News

Teva neurology news

Teva will pay $1.2 billion to settle a 2008 Federal Trade Commission antitrust suit alleging that Cephalon Inc. , which Teva acquired in 2011, paid generic drug manufacturers more than $200 million to drop challenges...
02:41 , May 29, 2015 |  BC Extra  |  Company News

Teva agrees to $1.2B pay-for-delay settlement

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will pay $1.2 billion to settle a Federal Trade Commission antitrust suit alleging that Cephalon Inc. , which Teva later acquired, paid generic drug manufacturers more than $200 million to...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Teva, Lupin deal

Teva granted Lupin rights to market 100 and 200 mg dosage strengths of a generic version of Teva's sleep disorder drug Nuvigil armodafinil 180 days after Actavis plc (NYSE:ACT, Dublin, Ireland) launches its generic version...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Teva, Novartis deal

Teva granted Novartis’ Sandoz Inc. generics unit rights to market 100 and 200 mg dosage strengths of a generic version of Teva’s sleep disorder drug Nuvigil armodafinil 180 days after Actavis plc (NYSE:ACT, Dublin, Ireland)...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Teva, Apotex deal

Teva granted Apotex rights to market 100 and 200 mg dosage strengths of a generic version of Teva's sleep disorder drug Nuvigil armodafinil 180 days after Actavis plc (NYSE:ACT, Dublin, Ireland) launches its generic version...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Teva, Actavis plc neurology, generics news

Teva's Cephalon Inc. subsidiary will grant Actavis rights to market generic versions of sleep disorder drug Nuvigil armodafinil to settle all patent litigation between the companies. Actavis can market 100 and 200 mg strengths of...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Apotex, Teva neurology news

On Dec. 16, 2013, the U.S. Supreme Court denied a petition from Teva's Cephalon Inc. subsidiary to review a decision from the U.S. Court of Appeals for the Federal Circuit (CAFC) in Apotex Inc. v....
07:00 , Sep 30, 2013 |  BioCentury  |  Regulation

Wake-up call

Narcolepsy patients told...